Core Insights - Premarket trading is showing notable activity with early price movements indicating potential opportunities before the market opens [1] Premarket Gainers - Galaxy Payroll Group Limited (GLXG) increased by 39% to $5.34 - Lithium Americas Corp. (LAC) rose by 31% to $7.52 - Senmiao Technology Limited (AIHS) gained 22% to $2.45 - The AES Corporation (AES) saw a 10% increase to $14.53 - Strive, Inc. (ASST) also increased by 10% to $2.77 - Shoulder Innovations, Inc. (SI) rose by 9% to $13.78 - Top KingWin Ltd (WAI) increased by 8% to $3.80 - Southland Holdings, Inc. (SLND) saw a 7% increase to $4.61 - CaliberCos Inc. (CWD) rose by 6% to $4.75 - Mannatech, Incorporated (MTEX) increased by 5% to $10.53 [3] Premarket Losers - Real Messenger Corporation (RMSG) decreased by 16% to $2.01 - Etoiles Capital Group Co., Ltd (EFTY) fell by 14% to $14.45 - Enanta Pharmaceuticals, Inc. (ENTA) dropped by 13% to $10.41 - CollPlant Biotechnologies Ltd. (CLGN) saw an 11% decrease to $2.39 - Fortress Biotech, Inc. (FBIO) declined by 10% to $3.30 - Uni-Fuels Holdings Limited (UFG) fell by 9% to $7.52 - Alset Inc. (AEI) decreased by 9% to $2.30 - JFB Construction Holdings (JFB) saw a 5% decline to $12.20 - SHF Holdings, Inc. (SHFS) dropped by 5% to $6.80 - Phio Pharmaceuticals Corp. (PHIO) decreased by 5% to $2.34 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SciSparc Ltd. (SPRC) is up 41% at $6.32 - Wolfspeed, Inc. (WOLF) is up 22% at $26.50 - Innovation Beverage Group Limited (IBG) is up 14% at $3.60 - Genasys Inc. (GNSS) is up 12% at $2.52 - Tamboran Resources Corporation (TBN) is up 9% at $24.84 - Fitell Corporation (FTEL) is up 8% at $6.09 - Zura Bio Limited (ZURA) is up 8% at $3.25 - Phio Pharmaceuticals Corp. (PHIO) is up 8% at $2.60 - AVITA Medical, Inc. (RCEL) is up 7% at $5.77 - Next Technology Holding Inc. (NXTT) is up 5% at $24.00 [3] Premarket Losers - Applied DNA Sciences, Inc. (APDN) is down 26% at $3.87 - Epsium Enterprise Limited (EPSM) is down 23% at $18.79 - Artelo Biosciences, Inc. (ARTL) is down 21% at $4.60 - Boqii Holding Limited (BQ) is down 14% at $8.52 - Top KingWin Ltd (WAI) is down 13% at $4.02 - bioAffinity Technologies, Inc. (BIAF) is down 13% at $2.82 - Firefly Aerospace Inc. (FLY) is down 12% at $36.96 - JFB Construction Holdings (JFB) is down 12% at $11.14 - Akanda Corp. (AKAN) is down 9% at $4.31 - Energy Fuels Inc. (UUUU) is down 6% at $15.41 [4]

Core Viewpoint - Phio Pharmaceuticals is advancing its clinical-stage siRNA gene silencing technology, INTASYL, aimed at treating skin cancer, with a focus on its lead product candidate PH-762, which is currently in a Phase 1b clinical trial [1][4]. Group 1: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PHIO, specializing in therapeutics that utilize its proprietary INTASYL® siRNA gene silencing technology [1][4]. - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]. Group 2: Clinical Trial Progress - The ongoing Phase 1b clinical trial for PH-762 is currently treating patients in its fifth cohort, indicating progress towards the anticipated final cohort [1][2]. - The trial is designed to evaluate PH-762 as a potential non-surgical treatment option for skin cancers [4]. Group 3: Upcoming Events - Phio Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, where the CEO will provide updates on the clinical trial and future strategies [1][2][8]. - One-on-one investor meetings will be available during the conference for interested parties [3].

Group 1: Phio Pharmaceuticals Corp. - Phio Pharmaceuticals Corp. is an immuno-oncology biotech company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 14.4% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 0.66, significantly lower than the industry average of 7.20 [2] Group 2: Transportadora de Gas del Sur S.A. - Transportadora de Gas del Sur S.A. is a midstream energy company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 4.6% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 19.11, which is comparable to the S&P average of 19.13 [3]

Core Viewpoint - Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its Phase 1b clinical trial of PH-762, a siRNA compound targeting skin cancer, to the fourth dose escalation cohort, indicating a supportive safety profile in the previous cohort [1][2]. Group 1: Clinical Trial Details - The Phase 1b clinical trial is a multi-center, dose-escalating study aimed at evaluating the safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma [2][6]. - In the third cohort, three patients with cutaneous squamous cell carcinoma were enrolled, and the injections were well tolerated with no serious adverse events or dose-limiting toxicities reported [2][4]. - Previous cohorts included seven patients, with the second cohort showing two patients achieving a complete response (100% tumor clearance) and one patient showing a partial response (90% clearance) [4]. Group 2: Company Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][6]. - The lead product candidate, PH-762, is designed to silence the PD-1 gene, which is implicated in various forms of skin cancer, and is being evaluated as a potential non-surgical treatment option [6][5]. - The company expresses optimism that PH-762 may provide a viable alternative to existing therapies for skin cancer [5].

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company announced podium presentations for its lead INTASYL product candidates, PH-762 and PH-894, at the 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany [1] Product Candidates - PH-762 is an INTASYL siRNA compound targeting PD-1, currently undergoing evaluation in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, showing promising preclinical efficacy and favorable tolerability [2][4] - PH-894 selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, representing a novel approach to improve adoptive cell therapy [3] Conference Presentations - Melissa Maxwell, Phio's Director of Research and Program Management, will present on PH-762 during the Plenary Session 3, focusing on its preclinical advances and ongoing clinical evaluation [2] - PH-894 will be discussed in Plenary Session 11, highlighting its potential to increase NK cell activity for adoptive cell therapy [3]

Core Insights - Phio Pharmaceuticals reported its financial results for the year ended December 31, 2024, and provided updates on its clinical trials and business strategy [1][10][14] Clinical Development - The lead product candidate, PH-762, is in a Phase 1b clinical trial for treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with the third cohort fully enrolled [2][3][16] - The trial has shown promising results, with complete tumor clearance in 2 patients and partial response in 1 patient from the second cohort [2][3] - The company expects to complete patient enrollment in the trial by the third quarter of 2025 [3] Financial Overview - As of December 31, 2024, the company had cash of approximately $5.4 million, down from $8.5 million in 2023 [10][19] - The company raised approximately $9.2 million through direct offerings and private placements in late 2024 and early 2025, along with an additional $2.9 million from warrant exercises [4][11] - Research and development expenses decreased by approximately $2.7 million, or 42%, compared to 2023, primarily due to cost rationalization measures [12] Cost Management - The company initiated a cost rationalization program in 2023, transitioning from discovery research to product development, which included headcount reductions and a smaller research footprint [5][6] - General and administrative expenses decreased by approximately 14% to $3.7 million in 2024, down from $4.4 million in 2023 [13] Patent and Scientific Advancements - Phio's patent portfolio includes 77 issued patents, with 69 covering its INTASYL technology, which is designed for cancer therapy [8] - The company presented new data on its INTASYL technology at several major conferences in 2024, highlighting its potential applications in immuno-oncology [9]